Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
Horizon began an open-label, U.S. Phase I trial to evaluate subcutaneous Actimmune every other day in combination with IV Opdivo nivolumab in patients with advanced solid tumors who have progressed o...
